{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:28:32Z","timestamp":1793381312139,"version":"4.5.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Psoriasis continues to have unmet needs in its management despite introduction of newer molecules. Monotherapy with these newer agents may not achieve therapeutic goals in all cases, hence necessitating their combinations with other molecules. Improved understanding of newer as well as conventional treatment modalities and experiences in their combinations hence necessitates therapeutic guidelines for their use in psoriasis.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To review the combinations of treatments reported in literature and recommendations for their use based on best current evidence in literature.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A literature review of MEDLINE database for studies evaluating combinations of newer therapies with conventional therapies in psoriasis was done. Newer therapies were identified as biologic disease modifying anti rheumatic drugs and other molecules such as apremilast while conventional therapies included methotrexate, cyclosporine, or retinoids, phototherapy and others. The therapeutic guidelines are proposed with the aim to provide evidenced based approach to combine newer and conventional agents in day-to-day psoriasis management.<\/jats:p><jats:p><jats:bold>Findings:<\/jats:bold> Combination of acitretin and narrow band ultraviolet B (NB-UVB)\/Psoralen with ultraviolet A (PUVA) achieves faster clearance and allows reduction of dose of the latter. A variable outcome is reported of methotrexate with TNF-\u03b1 inhibitors vs. TNF-\u03b1 inhibitors alone, although addition of methotrexate appears to reduce immunogenicity of TNF-\u03b1 inhibitors thereby preventing formation of anti-drug antibodies especially in case of infliximab. While combination of acitretin and PUVA is beneficial, combining TNF-\u03b1 inhibitors and phototherapy too produces better and faster results but long term risks of Non Melanoma Skin Cancers (NMSCs) may preclude their use together. Combination of cyclosporine and phototherapy is not recommended due to greater chances of NMSCs. Adding phototherapy to Fumaric Acid Esters (FAEs) improves efficacy. Apremilast can be safely combined with available biologic agents in patients with plaque psoriasis or psoriatic arthritis not responding adequately to biologics alone. Hydroxyurea and acitretin may be used together increasing their efficacy and reducing doses of both and hence their adverse effects.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Selected clinical scenarios shall benefit from combinations therapies, improving efficacy of both conventional and newer agents and at the same time helping reduce toxicity of higher dosages when used individually.<\/jats:p>","DOI":"10.3389\/fmed.2021.696597","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T06:57:39Z","timestamp":1629356259000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Systematic Review and Recommendations to Combine Newer Therapies With Conventional Therapy in Psoriatic Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Sandeep","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulhima","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.4103\/ijdvl.IJDVL_298_18","article-title":"PLA2R antibody positive membranous glomerulonephropathy associated with psoriasis vulgaris","volume":"85","author":"Arora","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2017.04.1133","article-title":"Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome","volume":"77","author":"Rodr\u00edguez-Z\u00fa\u00f1iga","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","article-title":"Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone","volume":"51","author":"Rosen","year":"2012","journal-title":"Rheumatol Oxf Engl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"rkaa033","DOI":"10.1093\/rap\/rkaa033","article-title":"Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis","volume":"4","author":"Rech","year":"2020","journal-title":"Rheumatol Adv Pract."},{"key":"B8","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman","year":"1990","journal-title":"J Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.det.2011.11.006","article-title":"Quality-of-life instruments: evaluation of the impact of psoriasis on patients","volume":"30","author":"Heller","year":"2012","journal-title":"Dermatol Clin."},{"key":"B11","unstructured":"Systemic, Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e14704","DOI":"10.1111\/dth.14704","article-title":"Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: a case series of high efficacy and safety profile","author":"Polat Ekinci","year":"2020","journal-title":"Dermatol Ther"},{"key":"B13","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can Fam Physician Med Fam Can."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","article-title":"Old and new biological therapies for psoriasis","volume":"18","author":"R\u00f8nholt","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/0190-9622(91)70253-X","article-title":"Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study","volume":"25","author":"Tanew","year":"1991","journal-title":"J Am Acad Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/0190-9622(91)70089-K","article-title":"Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone","volume":"24","author":"Lowe","year":"1991","journal-title":"J Am Acad Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/09546634.2011.607795","article-title":"A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept","volume":"23","author":"Lynde","year":"2012","journal-title":"J Dermatol Treat."},{"key":"B18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1468-3083.2012.04611.x","article-title":"A randomized, \u201chead-to-head\u201d pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients","volume":"27","author":"Park","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/bjd.12277","article-title":"Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis","volume":"169","author":"Calzavara-Pinton","year":"2013","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/j.1365-2133.2011.10358.x","article-title":"Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks","volume":"164","author":"Gambichler","year":"2011","journal-title":"Br J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2133.2011.10616.x","article-title":"Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial","volume":"166","author":"Wolf","year":"2012","journal-title":"Br J Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1468-3083.2009.03486.x","article-title":"Methotrexate\/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis\u2013a randomized single-blinded placebo-controlled study","volume":"24","author":"Mahajan","year":"2010","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2006.01.004","article-title":"Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study","volume":"54","author":"Asawanonda","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/ijd.12444","article-title":"Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis","volume":"53","author":"Al-Hamamy","year":"2014","journal-title":"Int J Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2340\/00015555-0511","article-title":"The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy","volume":"88","author":"Zachariae","year":"2008","journal-title":"Acta Derm Venereol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"Br J Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.intimp.2019.05.042","article-title":"Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis","volume":"73","author":"Yu","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","article-title":"Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate","volume":"78","author":"van Mens","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","article-title":"GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis","volume":"79","author":"Vieira-Sousa","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12895-016-0048-z","article-title":"A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/j.1365-2133.2008.08564.x","article-title":"Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial","volume":"158","author":"Gisondi","year":"2008","journal-title":"Br J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000448135","article-title":"Combination therapy of etanercept and fumarates versus etanercept monotherapy in psoriasis: a randomized exploratory study","volume":"232","author":"van Bezooijen","year":"2016","journal-title":"Dermatol Basel Switz."},{"key":"B35","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/bjd.16106","article-title":"Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study","volume":"178","author":"Tzaneva","year":"2018","journal-title":"Br J Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S0190-9622(96)90722-7","article-title":"Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D3) on vitamin D photosynthesis in patients with psoriasis","volume":"35","author":"Prystowsky","year":"1996","journal-title":"J Am Acad Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2340\/00015555-0290","article-title":"Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis","volume":"87","author":"Ezquerra","year":"2007","journal-title":"Acta Derm Venereol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archdermatol.2009.5","article-title":"Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial","volume":"145","author":"Mittal","year":"2009","journal-title":"Arch Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/09546630903460260","article-title":"Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative","volume":"22","author":"el-Mofty","year":"2011","journal-title":"J Dermatol Treat."},{"key":"B40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1600-0781.2011.00594.x","article-title":"311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients","volume":"27","author":"Wolf","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B41","first-page":"366","article-title":"Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis","volume":"10","author":"Bagel","year":"2011","journal-title":"J Drugs Dermatol."},{"key":"B42","first-page":"957","article-title":"Apremilast and narrowband ultraviolet-B combination therapy for treating moderate-to-severe plaque psoriasis","volume":"16","author":"Bagel","year":"2017","journal-title":"J Drugs Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1111\/ced.14000","article-title":"Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis","volume":"44","author":"Sacchelli","year":"2019","journal-title":"Clin Exp Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/ijd.IJD_548_18","article-title":"Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic","volume":"64","author":"De","year":"2019","journal-title":"Indian J Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/bjd.16899","article-title":"Hydroxyurea and acitretin as a novel combination therapy in severe plaque psoriasis","volume":"179","author":"Narang","year":"2018","journal-title":"Br J Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0190-9622(89)70236-X","article-title":"A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis","volume":"21","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2133.1989.tb01406.x","article-title":"A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis","volume":"121","author":"Lauharanta","year":"1989","journal-title":"Br J Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00412661","article-title":"Therapy of psoriasis with retinoid plus PUVA: clinical and histologic data","volume":"264","author":"Heidbreder","year":"1979","journal-title":"Arch Dermatol Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/09546634.2012.746634","article-title":"Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how","volume":"24","author":"Bettoli","year":"2013","journal-title":"J Dermatol Treat."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","article-title":"Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study","volume":"13","author":"Bavinck","year":"1995","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3389\/fimmu.2019.02515","article-title":"The TNF paradox in cancer progression and immunotherapy","volume":"10","author":"Montfort","year":"2019","journal-title":"Front Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for psoriasis and the risk of malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/rheumatology\/kem214","article-title":"Skin cancer in psoriatic arthritis treated with anti-TNF therapy","volume":"46","author":"Sheppard","year":"2007","journal-title":"Rheumatol Oxf Engl."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/j.1365-2133.2010.09663.x","article-title":"Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe?","volume":"162","author":"Di Lernia","year":"2010","journal-title":"Br J Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2013Update 2015\u2013Short version\u2013EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/bjd.12654","article-title":"Antidrug antibodies in psoriasis: a systematic review","volume":"170","author":"Hsu","year":"2014","journal-title":"Br J Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjd.12341","article-title":"Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study","volume":"169","author":"Mahil","year":"2013","journal-title":"Br J Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jaad.2011.10.020","article-title":"The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study","volume":"67","author":"Gottlieb","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1346-8138.2010.00882.x","article-title":"Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study","volume":"37","author":"Adi\u015fen","year":"2010","journal-title":"J Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet Lond Engl."},{"key":"B64","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1136\/ard.2010.130864","article-title":"Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study","volume":"70","author":"Atzeni","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/1573397115666181130094455","article-title":"Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis","volume":"15","author":"Metyas","year":"2019","journal-title":"Curr Rheumatol Rev."},{"key":"B66","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/1346-8138.15193","article-title":"Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue","volume":"47","author":"Takamura","year":"2020","journal-title":"J Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1203475416631328","article-title":"Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study","volume":"20","author":"AbuHilal","year":"2016","journal-title":"J Cutan Med Surg."},{"key":"B68","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/247553031117a00302","article-title":"Hydroxyurea for the treatment of psoriasis including in HIV-infected individuals: a review","volume":"17","author":"Lee","year":"2011","journal-title":"Psoriasis Forum."},{"key":"B69","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.7973634","article-title":"Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication","volume":"266","author":"Lori","year":"1994","journal-title":"Science."},{"key":"B70","first-page":"274","article-title":"Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment","volume":"196","author":"Salmon-Ehr","year":"1998","journal-title":"Dermatol Basel Switz."},{"key":"B71","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/archderm.107.3.369","article-title":"Combined methotrexate and hydroxyurea therapy for psoriasis","volume":"107","author":"Sauer","year":"1973","journal-title":"Arch Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.696597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T06:57:48Z","timestamp":1629356268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.696597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":71,"alternative-id":["10.3389\/fmed.2021.696597"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.696597","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"article-number":"696597"}}